



Patent Docket P0987R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

|                                     |   |            |
|-------------------------------------|---|------------|
| In re Application of                | Group Art Unit: 1642  | SEP 6 1999 |
| Martin M. Bednar et al.             | Examiner: P. Gambel   | GROUP 1800 |
| Serial No.: 08/788,800              | <b>CERTIFICATE OF MAILING</b><br>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on<br><br>August 24, 1998<br><br><i>Joyce Cohen</i><br>Joyce Cohen |            |
| Filed: January 22, 1997             |   |            |
| For: ANTI-CD18 ANTIBODIES IN STROKE |   |            |

13/B  
A.G.J.  
9/10/98

AMENDMENT UNDER 37 C.F.R. §1.111

Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

Responsive to the official action dated May 28, 1998 in the above-identified application, Applicants respectfully request reconsideration in view of the following amendments and remarks.

In the Specification

Page 1, line 15, change "60/\_\_\_ (to be assigned)" to -- 60/093,038 --.

In the Claims

Please amend the claims as follows:

1. (Twice Amended) A method for treating focal ischemic stroke caused by obstruction of a main cerebral artery in a human mammal comprising administering an amount of an anti-CD18 antibody to the mammal which is effective for increasing cerebral blood flow or reducing infarct size, in the absence of removal of the arterial obstruction, wherein at least one of the following conditions is present:

(a) the antibody binds to an extracellular domain of CD18 and inhibits or reduces CD18 biological activity.

(b) the antibody binds CD18 with an affinity of 4 nm or less, or

42